Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Stahl, S. M. Articles by Grady, M. M. Search for Related Content PubMed Citation Articles by Stahl, S. M. Articles by Grady, M. M. Costs, Cost Analysis Health Insurance Atypical Neuroleptics

High-Cost Use of Second-Generation Antipsychotics Under California's Medicaid Program

OBJECTIVE: The high costs associated with second-generation antipsychotic medications raise concerns that prior-authorization restrictions may be implemented to restrict use. This study assessed patterns of antipsychotic use to identify uses that are associated with high economic cost but for which there is no documented efficacy. METHODS: California Medicaid fee-for-service pharmacy claims were analyzed from May 1999 through August 2000 for patients who received risperidone, olanzapine, or quetiapine. RESULTS: Of the 116,114 patients who received at least one of these agents, 4.1 percent received a combination regimen. Polypharmacy was the most expensive form of second-generation antipsychotic use, costing up to three times more per patient than monotherapy. CONCLUSION: Restricting polypharmacy may reduce costs and prevent the need for prior-authorization restrictions.

This article has been cited by other articles:

				M. HAZRA, D. C. MAMO, and G. REMINGTON Adjunctive Versus Monotherapeutic Treatment for Schizophrenia: Addressing Antipsychotic Side Effects Am J Psychiatry, March 1, 2008; 165(3): 396 - 397. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2006 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us